OBGYN.net Founder Joins CytoCore as Consultant.

CHICAGO -- CytoCore, Inc. (OTCBB:MCDG) announced today the engagement of Roberta Speyer, CEO of MediSpecialty Inc., publishers of OBGYN.net, as a consultant to the firm. MediSpecialty is a leader in developing interactive communications for the healthcare industry. Over the past decade they have worked with an extensive network of clients including many Fortune 500 companies. They are especially responsive to early stage companies in the pharmaceutical, medical device and bio-tech fields.

Roberta Speyer, CEO of MediSpecialty the creators of the premier web site for obstetrics, gynecology and women's health, www.OBGYN.net had this to say, "OBGYN.net has been supporting the GYN medical sector for 10 years and is the leading OB/GYN site on the internet, interacting with tens of thousands of physicians world wide. I personally applaud CytoCore's efforts to commercialize its e2 Collector and the Endometrial Cancer Scan because I believe early diagnosis and successful treatment of gynecologic cancers is the next big milestone to be met in improving women's healthcare. These types of cancers historically did not get enough attention in the media and we are committed to changing that. The recent FDA approval of Gardasil, the vaccine to prevent HPV is creating awareness in the women's health community of the importance of early diagnosis and treatment. This will ultimately benefit young women. But what of the vast community already at risk? Making CytoCore's products commercially available will go a long way to avoid needless suffering. We are very pleased to be involved with the Company's efforts to bring these products to market.

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.